GSK kicks off large trial to test shingles vaccine for dementia prevention

GSK is launching a large study to determine whether the shingles vaccine Shingrix can lower dementia risk, prompted by observational data suggesting vaccinated individuals may have fewer dementia cases; the trial aims to establish causality and could influence dementia prevention strategies if results are favorable.